Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Molecular FormulaC45H39F3N6O7 |
InChIKeyFHYJXONYZYZLTJ-LLIHCOLESA-N |
CAS Registry2971850-36-7 |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Neoplasms | Preclinical | United States | 15 Sep 2023 | |
| Neoplasms | Preclinical | United States | 15 Sep 2023 |





